atracurium besylate / Generic mfg. - LARVOL DELTA

Identification of effective synthetic molecules against viral-induced cytokine release syndrome using in silico and in vitro approaches. (PubMed, Mol Divers) - "Six potential 3-CLpro inhibitors were identified by molecular docking using MOE software, including ebastine (1), orlistat (2), atracurium besylate (3), piperaquine phosphate (4), valsartan (5), and acarbose (6), among which 1-3 binds strongly to the target protein with binding affinity of - 8.22, - 9.12, and - 7.81, kcal/mol, respectively. This study demonstrates the potential of pre-existing drugs to ameliorate the cytokine storm and oxidative damage with simultaneous anti-viral effects. The data provide pre-clinical support to develop these drugs as potential therapeutic agent against ARDS."

Journal • Preclinical • Acute Respiratory Distress Syndrome • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • CSF2 • IFNG • IL1B • IL2 • IL6 • TNFA

Lethal Self-Administration of Atracurium: A Rarely Reported Case with Review of Literature. (PubMed, Am J Forensic Med Pathol) - "Atracurium besylate is a nondepolarizing skeletal muscle relaxant first introduced in 1980...The toxicological analysis report indicated the presence of laudanosine in the vitreous humor, blood, urine, and skin from the puncture site and underneath vein. Also, the toxicological analysis of the empty syringe found at the crime scene revealed the presence of atracurium, confirming that the victim had administered a lethal dose of atracurium."

Journal • Review

An Experimental Study to Optimize Neuromuscular Blockade Protocols in Cynomolgus Macaques: Monitoring, Doses, and Antagonism. (PubMed, J Med Primatol) - "These results support the use of non-human primate models for neuromuscular block monitoring. This represented the first step before the forthcoming testing of new NMBA-reversal agents."

Journal • Anesthesia • Critical care

Small Doses Muscle Relaxant in General Anesthesia (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Mansoura University | Trial completion date: Dec 2024 ➔ Jun 2026 | Trial primary completion date: Jul 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Anesthesia

Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Tata Memorial Centre | N=40 ➔ 0 | Unknown status ➔ Withdrawn

Biomarker • Enrollment change • Surgery • Trial withdrawal • Anesthesia • Breast Cancer • Oncology • Solid Tumor • HIF1A • VEGFC

Small Doses Muscle Relaxant in General Anesthesia (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Mansoura University | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Nov 2022 ➔ Jul 2024

Trial completion date • Trial primary completion date • Anesthesia

Quadratus Lumborum Versus Transversus Abdominis Plane Block Versus Caudal Block for Postoperative Analgesia After Pediatric Inguinal Hernia : Double-Blinded Randomized Trial (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Tanta University

New trial • Gastroenterology • Pain • Pediatrics

CARRENAL: New Approach of Loco Regional Analgesia in Kidney Transplant (clinicaltrials.gov) - P=N/A | N=48 | Recruiting | Sponsor: CHU de Reims

New trial • Chronic Kidney Disease • Nephrology • Renal Disease • Transplantation

Small Doses Muscle Relaxant in General Anesthesia (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Mansoura University | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Nov 2021 ➔ Nov 2022

Trial completion date • Trial primary completion date • Anesthesia

Effect of Local Anesthesia Versus Induced Hypotensive Anesthesia on Quality of External Dacryocystorhinostomy Operation (clinicaltrials.gov) - P=N/A | N=64 | Not yet recruiting | Sponsor: Mansoura University

New trial • Anesthesia

Effect of Atracurium and Rocuronium on the State and Response Entropy During Isoflurane Anesthesia (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Ain Shams University

New P1 trial • Anesthesia • Mood Disorders

Small Doses Muscle Relaxant in General Anesthesia (clinicaltrials.gov) - P=N/A; N=60; Recruiting; Sponsor: Mansoura University; Trial completion date: Mar 2021 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Nov 2021

Trial completion date • Trial primary completion date • Anesthesia

Small Doses Muscle Relaxant in General Anesthesia (clinicaltrials.gov) - P=N/A; N=60; Recruiting; Sponsor: Mansoura University; Not yet recruiting ➔ Recruiting; Trial completion date: Oct 2020 ➔ Mar 2021; Trial primary completion date: Sep 2020 ➔ Dec 2020

Enrollment open • Trial completion date • Trial primary completion date • Anesthesia

Effects of neuromuscular blocking drugs on viability of human umbilical vein endothelial cells (HUVECs). (PubMed, J Int Med Res) - "The findings of the current study support the safety of the studied neuromuscular blocking drugs in clinically relevant concentrations regarding their effects on endothelial cell proliferation."

Journal

[VIRTUAL] Nicotinic receptors on nerve terminals induce acetylcholine release in canine bladder (AUA 2020) - "Introduction: Carbachol, a mixed muscarinic and nicotinic agonist similar to acetylcholine, is often used for in-vitro bladder contraction with the implicit assumption that it causes contraction by only activating bladder smooth muscle muscarinic receptors...Blocking sodium channels with 1 uM tetrodotoxin (TTX) had no statistically significant inhibitory effect on epibatidine or nicotine induced contractions... Because of atropine blockade but only minor blockade by a,ß methylene ATP desensitization, the nicotinic agonists induce bladder contractions indirectly by releasing predominately acetylcholine from intramural nerve terminals. Because TTX was ineffective, these nicotinic receptors do not need to induce action potentials and thus are likely located near the neuromuscular junction. Based on the pharmacological data, the a3ß4 receptor subtype is likely involved in contraction of the canine bladder."

Bladder Cancer • Solid Tumor

Small Doses Muscle Relaxant in General Anesthesia (clinicaltrials.gov) - P=N/A; N=60; Not yet recruiting; Sponsor: Mansoura University

New trial

"Inequities from NTDs keep populations in cycles of disease and poverty. @AKrentel work @bruyerecare and through @BruyereResearch making important inroads into #beatNTDs." (@Heidi_Sveistrup)

Clinical